Subcutaneous Immunotherapy Improves the Symptomatology of Allergic Rhinitis

Abstract

Introduction The relevance of allergic rhinitis is unquestionable. This condition affects people's quality of life and its incidence has increased over the last years.

Objective Thus, this study aims to analyze the effectiveness of subcutaneous injectable immunotherapy in cases of nasal itching, sneeze, rhinorrhea and nasal congestion in allergic rhinitis patients.

Methods In the present study, the same researcher analyzed the records of 281 patients. Furthermore, the researchers identified allergens through puncture cutaneous tests using standardized extracts containing acari, fungi, pet hair, flower pollen, and feathers. Then, the patients underwent treatment with subcutaneous specific immunotherapy, using four vaccine vials for desensitization, associated with environmental hygiene. The authors analyzed conditions of nasal itching, sneeze, rhinorrhea, and nasal congestion throughout the treatment, and assigned them with a score ranging from zero (0), meaning absence of these symptoms to three (3), for severe cases. The symptoms were statistically compared in the beginning, during, and after treatment.

Results In this study, authors analyzed the cases distribution according to age and the evolution of symptomatology according to the scores, comparing all phases of treatment. The average score for the entire population studied was 2.08 before treatment and 0.44 at the end. These results represent an overall improvement of ∼79% in symptomatology of allergic rhinitis in the studied population.

Conclusion The subcutaneous immunotherapy as treatment of allergic rhinitis led to a reduction in all symptoms studied, improving the quality of life of patients, proving itself as an important therapeutic tool for these pathological conditions.

Keywords

allergy - rhinitis - hypersensitivity - allergen immunotherapy - injections - subcutaneous - symptoms

• References

• 1 Arbes Jr SJ, Gergen PJ, Elliott L, Zeldin DC. Prevalence of positive skin test responses to 10 common allergens in the US population: results from the third National Health and Nutrition Examination Survey. J Allergy Clin Immunol 2005; 116 (2) 377-383
• 2 Calderon MA, Alves B, Jacobson M, Hurwitz B, Sheikh A, Durham S. Allergen injection immunotherapy for seasonal allergic rhinitis. Cochrane Database Syst Rev 2007; (1) CD001936 Comment in: Otolaryngol Head Neck Surg. 2007;136(4):511–4
• 3 Soler R, Carrillo T. Alergia: a epidemia do século XX. In: Allergy Conference Reports: Proceedings of the XXth Congress of the European Academy of Allergology and Clinical Immunology (Berlin, Germany) 2001;3–4
• 4 Solé D, Wandalsen GF, Camelo-Nunes IC, Naspitz CK . ISAAC - Brazilian Group. Prevalence of symptoms of asthma, rhinitis, and atopic eczema among Brazilian children and adolescents identified by the International Study of Asthma and Allergies in Childhood (ISAAC) - Phase 3. J Pediatr (Rio J) 2006; 82 (5) 341-346
• 5 Schultz A, Stuck BA, Feuring M, Hörmann K, Wehling M. Novel approaches in the treatment of allergic rhinitis. Curr Opin Allergy Clin Immunol 2003; 3 (1) 21-27
• 6 Baena-Cagnani CE. Allergic Rhinitis and its Impact on Asthma (ARIA) in Latin America. Rev Alerg Mex 2002; 49 (6) 181-188
• 7 McCrory DC, Williams JW, Dolor RJ , et al. Management of Allergic Rhinitis in the Working-Age Population. Evidence Reports/Technology Assessment Number 67 (Prepared by Duke Evidence-based Practice Center under Contract Number 290–97–0014). Agency for Healthcare Research and Quality (US) Publication Number 03–E015. ISBN-10: 1–58763–077-X. Rockville, MD: Agency for Healthcare Research and Quality. March 2003
• 8 Blaiss MS. Allergic rhinitis: Direct and indirect costs. Allergy Asthma Proc 2010; 31 (5) 375-380
• 9 Mohapatra SS, Qazi M, Hellermann G. Immunotherapy for allergies and asthma: present and future. Curr Opin Pharmacol 2010; 10 (3) 276-288 10.1016/j.coph.2010.05.012
• 10 Demoly P, Dhivert-Donnadieu H, Bousquet J. Vaccinations aux allergenes chez l'enfant. Allerg Immunol (Paris) 2000; 32 (10) 397-401
• 11 Hankin CS, Cox L, Bronstone A. The health economics of allergen immunotherapy. Immunol Allergy Clin North Am 2011; 31 (2) 325-341 , x
• 12 Cox LS. How safe are the biologicals in treating asthma and rhinitis?. Allergy Asthma Clin Immunol 2009; 5 (1) 4
• 13 Senti G, Prinz Vavricka BM, Erdmann I , et al. Intralymphatic allergen administration renders specific immunotherapy faster and safer: a randomized controlled trial. Proc Natl Acad Sci U S A 2008; 105 (46) 17908-17912
• 14 Ohashi Y, Nakai Y, Tanaka A, Kakinoki Y, Washio Y, Nakai Y. Allergen-specific immunotherapy for allergic rhinitis: a new insight into its clinical efficacy and mechanism. Acta Otolaryngol Suppl 1998; 538 (Suppl. 01) 178-190
• 15 Polzehl D, Keck T, Riechelmann H. [Analysis of the efficacy of specific immunotherapy with house-dust mite extracts in adults with allergic rhinitis and/or asthma]. Laryngorhinootologie 2003; 82 (4) 272-280
• 16 Jones N. Allergic rhinitis: aetiology, predisposing and risk factors. Rhinology 2004; 42 (2) 49-56
• 17 Grevers G, Röcken M Eds. Atlas de Alergologia: fundamentos, diagnóstico e tratamento. Rio de Janeiro, Brazil: Artmed [6 volumes, 287p.]; 2001
• 18 Inal A, Altintas DU, Yilmaz M, Karakoc GB, Kendirli SG, Sertdemir Y. Prevention of new sensitizations by specific immunotherapy in children with rhinitis and/or asthma monosensitized to house dust mite. J Investig Allergol Clin Immunol 2007; 17 (2) 85-91
• 19 Varney VA, Tabbah K, Mavroleon G, Frew AJ. Usefulness of specific immunotherapy in patients with severe perennial allergic rhinitis induced by house dust mite: a double-blind, randomized, placebo-controlled trial. Clin Exp Allergy 2003; 33 (8) 1076-1082
• 20 Sade K, Roitman D, Kivity S. Sensitization to Dermatophagoides, Blomia tropicalis, and other mites in atopic patients. J Asthma 2010; 47 (8) 849-852
• 21 Krishna MT, Huissoon AP. Clinical immunology review series: an approach to desensitization. Clin Exp Immunol 2011; 163 (2) 131-146
• 22 Abramson MJ, Puy RM, Weiner JM. Injection allergen immunotherapy for asthma. Cochrane Database Syst Rev 2010; 8 (8) CD001186
• 23 Bousquet J, Lockey R, Malling HJ. Allergen immunotherapy: therapeutic vaccines for allergic diseases. A WHO position paper. J Allergy Clin Immunol 1998; 102 (4 Pt 1): 558-562 [PubMed: 9802362]
• 24 Crameri R. Allergy diagnosis, allergen repertoires, and their implications for allergen-specific immunotherapy. Immunol Allergy Clin North Am 2006; 26 (2) 179-189 , v [PubMed: 16701139]
• 25 Cox L, Cohn JR. Duration of allergen immunotherapy in respiratory allergy: when is enough, enough?. Ann Allergy Asthma Immunol 2007; 98 (5) 416-426
• 26 Karakaya G, Sahin S, Fuat Kalyoncu A. Erythema multiforme: As a complication of allergen-specific immunotherapy. Allergol Immunopathol (Madr) 2001; 29 (6) 276-278
• 27 Pfaar O, Klimek L, Sager A, Bräutigam M. Safety of a depigmented, polymerized vaccine for the treatment of allergic rhinoconjunctivitis and allergic asthma. Am J Rhinol Allergy 2010; 24 (3) 220-225
• 28 Durham SR, Walker SM, Varga E-M , et al. Long-term clinical efficacy of grass-pollen immunotherapy. N Engl J Med 1999; 341 (7) 468-475
• 29 Robinson DS. Allergen immunotherapy: does it work and, if so, how and for how long?. Thorax 2000; 55 (Suppl. 01) S11-S14
• 30 Ukai K, Amesara R, Masuda S , et al. The evaluation of hyposensitization with house dust in patients with nasal allergy to house dust-mite. Arerugi 1994; 43 (1) 16-21
• 31 Baptistella E, Maniglia S, Malucelli DA , et al. Allergen-specific immunotherapy in patients 55 years and older: Results and review of literature. Int Arch Otorhinolaryngol 2013; 17: 375-379
• 32 Tworek D, Bochenska-Marciniak M, Kuprys-Lipinska I, Kupczyk M, Kuna P. Perennial is more effective than preseasonal subcutaneous immunotherapy in the treatment of seasonal allergic rhinoconjunctivitis. Am J Rhinol Allergy 2013; 27 (4) 304-308
• 33 Pajno GB, Barberio G, De Luca F, Morabito L, Parmiani S. Prevention of new sensitizations in asthmatic children monosensitized to house dust mite by specific immunotherapy. A six-year follow-up study. Clin Exp Allergy 2001; 31 (9) 1392-1397